# Godrej Consumer Products ElaraCapital



India | FMCG | Result Update

## Market share gain amid weak demand

25 January 2025

37

Godrej Consumer Product (GCPL) remains cautious based on the urban demand outlook as the industry is witnessing a slowdown while rural market demand is gradually improving. Consumer downgrading was visible in the household insecticides (HI) and air care categories. However, GCPL has been gaining market share amid slower growth in soaps and HI. We expect volume and realization growth to improve in the domestic business from Q4, supported by continued market share gains and price increase in soaps. Despite near-term challenges, we project a 12% EBITDA CAGR during FY25E-27E, driven by high single-digit sales growth and margin expansion in the domestic and international businesses. Considering near-term challenges, we cut our target P/E to 48x (from 50x) and lower our TP of INR 1,260 as we roll forward to FY27E. We reiterate

Muted performance in HI and personal wash in the domestic business: Q3 net sales grew 3% YoY to INR 37.7bn, 1.4% ahead of our estimates, dragged by weak performance in India and the African Union (AU) business. In India, sales rose 4%, with flat volume hit by the urban slowdown, inflation-led price hikes in soaps causing trade destocking, and a poor season for HI. While air care and fabric wash achieved double-digit volume growth, and hair color saw mid -single-digit growth, HI was negatively affected by a weak season and muted growth in premium format sales. However, newly launched incense sticks reported robust growth, reaching a high single-digit market share from 5% in Q2. The new liquid vaporizer rolled across channels and is likely to be completed by March 2025 and Q1FY26 would provide more clarity on consumer response. Personal wash faced mid-to-high, single-digit volume decline due to trade destocking amid price hikes but outperformed the industry. Internationally, Indonesia grew 8% on constant currency terms with 6% volume growth, while the AU, the US, and the Middle East (GAUM) saw 1% growth in constant currency.

Demand stress continues in urban; Q4 to witness improved performance: GCPL rural market growth outpaced urban markets, driven by van operations. In urban regions, the company is experiencing slower growth in modern trade (MT) and its premium portfolio, alongside a downtrading in the HI segment. It anticipates a recovery in domestic volume, with high single-digit growth in the next couple of quarters, with Q4 volume and value growth showing an improvement from Q3 levels. GAUM is likely to see improved sales growth from Q4 as the trade stock reduction is largely completed.

Weak India margin weighs on profitability: In Q3, EBITDA margin contracted 290bp YoY to 20.1%, as we had expected, dragged by 710bp contraction in India. GCPL expects Q4 India business margin to remain similar to Q3, due to the mismatch in price hike and higher palm oil prices. For FY26, it projects India margin at the lower end of the 24-26% range.

Retain Accumulate with a lower TP of INR 1,260: We cut our EPS by 1.7%, 5.2% in FY26E and 3.8% for FY27E, due to lower-than-expected margin. We reiterate Accumulate with a lower TP of INR 1,260 from INR 1,330 on 48x (from 50x) P/E due to near-term demand challenges) as we roll forward to FY27E. Key risks are increased competition in the soap segment and lower-than-estimated growth in HI.

## **Key financials**

YE March	FY23	FY24	FY25E	FY26E	FY27E
Revenue (INR mn)	133,160	140,961	143,074	156,758	170,639
YoY (%)	8.5	5.9	1.5	9.6	8.9
EBITDA (INR mn)	24,305	29,435	30,051	33,628	37,782
EBITDA margin (%)	18.3	20.9	21.0	21.5	22.1
Adj PAT (INR mn)	17,566	19,163	19,828	23,624	26,916
YoY (%)	(2.0)	9.1	3.5	19.1	13.9
Fully DEPS (INR)	17.2	18.7	19.4	23.1	26.3
RoE (%)	13.9	14.5	14.9	15.8	16.1
RoCE (%)	16.8	19.3	19.5	21.1	21.5
P/E (x)	65.8	60.3	58.3	48.9	42.9
EV/EBITDA (x)	47.8	40.2	38.9	34.4	30.2

Note: Pricing as on 24 January 2025; Source: Company, Elara Securities Estimate

Rating: Accumulate

Target Price: INR 1,260

Upside: 12%

CMP: INR 1,130


As on 24 January 2025

Key data	
Bloomberg	GCPL IN
Reuters Code	GOCP.NS
Shares outstanding (mn)	1023
Market cap (INR bn/USD mn)	1156/13411
Enterprise Value (INR bn/USD mn)	1165/13515
Avg daily volume 3M (INR mn/USD mn)	1955/23
52 week high/low	1542/1055

Note: as on 24 January 2025: Source: Bloombera

#### Price chart

Free float (%)



Source: Bloomberg

Shareholding (%)	Q4	Q1	Q2	Q3
	FY24	FY25	FY25	FY25
Promoter	63.2	63.0	63.0	53.0
% Pledged	0.7	0.7	0.7	0.8
FII	22.6	22.4	22.0	20.7
DII	9.0	9.4	9.8	11.1
Others	5.2	5.2	5.2	15.2

Source: BSE

Price performance (%)	3M	6M	12M
Nifty	(5.4)	(5.4)	7.6
Godrej Consumer Products	(9.9)	(22.5)	(2.8)
NSE Mid-cap	(5.5)	(6.3)	12.3
NSE Small-cap	(7.1)	(9.4)	10.6

**Amit Purohit** Building Materials, FMCG, Paints +91 22 6164 8594 amit.purohit@elaracapital.com

Associates Rohit Harlikar





## Financials (YE March)

Income statement (INR mn)	FY23	FY24	FY25E	FY26E	FY27E
Net Revenue	133,160	140,961	143,074	156,758	170,639
EBITDA	24,305	29,435	30,051	33,628	37,782
Less: Depreciation & Amortization	2,363	2,410	2,250	2,302	2,323
EBIT	21,942	27,025	27,801	31,326	35,459
Less: Interest Expense	1,757	2,964	2,823	2,623	2,623
Add: Other Income	1,684	2,690	3,055	3,461	3,767
Exceptional item	(541)	(24,769)	-	-	-
PBT	21,327	1,982	28,033	32,164	36,603
Less Taxes	4,303	7,588	8,205	8,540	9,687
Reported PAT	17,025	(5,606)	19,828	23,624	26,916
Reported PAT after Minority Interest	17,025	(5,606)	19,828	23,624	26,916
Adjusted PAT	17,566	19,163	19,828	23,624	26,916
Balance Sheet (INR mn)	FY23	FY24	FY25E	FY26E	FY27E
Share capital	1,023	1,023	1,023	1,023	1,023
Reserves	136,920	124,963	139,441	156,659	176,245
Borrowings	10,340	31,546	16,546	13,546	13,546
Deferred Tax (Net)	(6,412)	(2,804)	(5,540)	(5,540)	(5,540)
Total Liabilities	141,870	154,729	151,470	165,688	185,274
Gross Block	54,168	69,616	72,116	75,616	79,116
Less: Accumulated depreciation	13,015	15,425	17,675	19,976	22,300
Net Block	41,152	54,191	54,441	55,639	56,816
Capital work in progress	416	782	782	782	782
Goodwill	58,223	50,264	50,264	50,264	50,264
Investments	30,290	35,037	35,037	35,037	35,037
Cash	3,907	5,469	1,836	13,325	29,967
Net working capital	7,882	8,986	9,111	10,642	12,410
Total Assets	141,870	154,729	151,470	165,688	185,274
Cash flow statement (INR mn)	FY23	FY24	FY25E	FY26E	FY27E
Operating cash flow	22,298	20,468	21,954	24,395	27,471
Less: Capex	8,796	7,855	2,500	3,500	3,500
Free cash flow to firm	13,501	12,613	19,454	20,895	23,971
Investing cash flow	(28,932)	(12,602)	(2,500)	(3,500)	(3,500)
Financing cash flow	(536)	(6,304)	(23,087)	(9,406)	(7,330)
Net change in cash	(7,170)	1,562	(3,633)	11,489	16,641
Ratio Analysis	FY23	FY24	FY25E	FY26E	FY27E
Income statement Ratios (%)					
Revenue growth	8.5	5.9	1.5	9.6	8.9
EBITDA growth	1.5	21.1	2.1	11.9	12.4
PAT growth	(2.0)	9.1	3.5	19.1	13.9
EBITDA margin	18.3	20.9	21.0	21.5	22.1
Net margin	13.2	13.6	13.9	15.1	15.8
Return and liquidity ratios					
Net debt/Equity (x)	0.0	0.2	0.1	0.0	(0.1)
ROE (%)	13.9	14.5	14.9	15.8	16.1
ROCE(%)	16.8	19.3	19.5	21.1	21.5
Per share data and Valuation ratios					
Diluted EPS (INR)	17.2	18.7	19.4	23.1	26.3
EPS growth (%)	(2.0)	9.1	3.5	19.1	13.9
DPS (INR)	-	5.0	5.2	6.3	7.2
P/E ratio (x)	65.8	60.3	58.3	48.9	42.9
EV/EBITDA (x)	47.8	40.2	38.9	34.4	30.2
EV/Sales (x)	8.7	8.4	8.2	7.4	6.7
Price/Book(x)					
	9.0	9.8	8.8	7.7	6.8
FCFF yield (%)	9.0 1.3	9.8	1.9	2.0	2.3
FCFF yield (%) Dividend yield (%)					

We expect a sales CAGR at 6.6% during FY24-27E

EBITDA CAGR at 8.7% during FY24-27E ahead of sales growth, led by margin expansion, especially in the international business

Note: Pricing as on 24 January 2025; Source: Company, Elara Securities Estimate



Sales growth of 3%, dragged by weak performance in the domestic business and trade stock correction in the GAUM business

EBITDA margin contracts on account of negative mix and palm oil inflation in the domestic business even as international margin expands strongly

## **Quarterly financials**

YE March (INR mn)	Q3FY25	Q3FY24	YoY (%)	Q2FY25	QoQ (%)	Q3FY25E	Variance (%)
Net Sales	37,684	36,596	3.0	36,663	2.8	37,150	1.4
Operating Expenses	30,125	28,189	6.9	29,067	3.6	29,647	1.6
% of Sales	79.9	77.0		79.3		79.8	
EBITDA	7,559	8,407	(10.1)	7,596	(0.5)	7,503	0.7
EBITDA Margin (%)	20.1	23.0		20.7		20.2	
Other Income	831	701	18.6	860	(3.4)	600	38.5
Interest	897	666		831		850	
Depreciation	619	539		501	23.5	500	23.8
PBT	6,874	7,903	(13.0)	7,124	(3.5)	6,753	1.8
Tax	1,834	2,024	(9.4)	2,154	(14.8)	1,959	(6.4)
Effective Tax Rate (%)	26.7	25.6		30.2		29.0	
Reported PAT	4,983	5,811	(14.2)	4,913	1.4	4,794	3.9
Adjusted PAT	5,041	5,880	(14.3)	4,971	1.4	4,794	5.1
NPM (%)	13.4	16.1		13.6		12.9	


Source: Company, Elara Securities Estimate

## **Exhibit 1: Key ratios**

YE March (%)	Q3FY25	Q3FY24	YoY bp chg	Q2FY25	QoQ bp chg	Q3FY25E	bp variance
Raw Material Cost	45.9	44.1	175	44.4	145	46.6	(70)
Staff Cost	7.9	7.5	31	8.5	(61)	7.6	24
Advertising Expenses	9.7	9.4	29	9.9	(26)	9.3	38
Other Expenses	16.6	16.0	56	16.5	8	16.3	21
Effective Tax rate	26.7	25.6	107	30.2	(355)	29.0	(233)
Gross Margin	54.1	55.9	(175)	55.6	(145)	53.4	70
EBITDA Margin	20.1	23.0	(291)	20.7	(66)	20.2	(14)
NPM	13.2	15.9	(265)	13.4	(18)	12.9	32


Source: Company, Elara Securities Estimate

Exhibit 2: Flat domestic volume due to muted performance in soaps and HI categories



Source: Company, Elara Securities Research

Exhibit 3: Weak margin in the domestic business drags profitability



Source: Company, Elara Securities Research



Exhibit 4: Domestic business – except for personal wash and HI, all other categories delivers good performance amid weak demand

Category	Q3 revenue growth (%)	Comments
Home care	4	<ul> <li>HI took a hit from relatively poor season</li> <li>Goodknight Agarbatti has seen outperformance and has gained significant market share, reaching high single digits in the incense sticks category. Premium formats have been hit by the urban consumption slowdown</li> <li>Air fresheners delivered double-digit volume growth</li> <li>Fabric care delivered strong double-digit volume growth with market share gains in liquid detergents</li> <li>New launches - GCPL launched the Mini Aer Pocket in a few states of South India at INR 30. Relaunched Aer Spray at INR 99 price point across India</li> </ul>
Personal care	2	<ul> <li>Personal wash posted mid-high, single-digit volume decline, almost offset by commensurate pricing growth, continues to witness cost pressures. Price increases for soaps is anticipated in Q4 as well</li> <li>Hair color volume grew in mid-single digits led by both Godrej Expert Rich Crème and Godrej Selfie Shampoo Hair Color growing in double digits</li> <li>Sexual wellness grew in value in the double digits while deodorants underperformed. Newly acquired RCCL portfolio's EBITDA margin is currently in the mid-teens (still away from the earlier aim of 25%) but better than a single-digit margin at acquisition</li> </ul>

Source: Company, Elara Securities Research

Exhibit 5: Robust growth in Indonesia; trade stock correction impacts GAUM performance

Country	Revenue (INR mn)	Revenue CC growth (%) gro		EBITDA margin (%)	EBITDA margin change (YoY)	Comments
Indonesia	5,080	9	8	21.5	+60bp	<ul> <li>Indonesia volumes grew by 6% YoY</li> <li>Stella Pocket continues its robust performance with volumes doubling YoY</li> <li>HI delivered volume growth in mid-teens on a two-year CAGR</li> <li>Hair colors recorded strong double-digit volume growth, led by shampoo Hair color</li> </ul>
GAUM (the AU, the US and the Middle East)	7,710	(16)	(7)	14.8	+340bp	The AU, the US and the Middle East (organic) sales declined by 8% in INR term and grew by 1% (CC terms) YoY Margin improved due to mix improvement and reduction in controllable cost
Others (LATAM and SAARC)	2,620	165	28	11.4	+1460bp	LATAM performs well with strong margin expansion


Source: Company, Elara Securities Research

## **Exhibit 6: Valuation**

	(INR)
EPS - FY26E	23.1
EPS - FY27E	26.3
Target multiple (x)	48
EPS - FY27E	26.3
Target price	1,260

Source: Elara Securities Estimate

Exhibit 7: GCPL trades around its five-year average P/E of 49x



Source: Bloomberg, Company, Elara Securities Estimate


Exhibit 8: Change in estimates

(INR mn)	Earlier			Revised			% Change		
	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E
Revenue	141,260	154,514	168,414	143,074	156,758	170,639	1.3	1.5	1.3
EBITDA	30,516	34,521	38,676	30,051	33,628	37,782	(1.5)	(2.6)	(2.3)
EBITDA margin (%)	21.6	22.3	23.0	21.0	21.5	22.1	(59.9)	(89.0)	(82.3)
PAT	20,163	24,914	27,973	19,828	23,624	26,916	(1.7)	(5.2)	(3.8)
EPS (INR)	19.7	24.4	27.3	19.4	23.1	26.3	(1.7)	(5.2)	(3.8)
TP (INR)			1,330			1,260			(5.3)

Source: Elara Securities Estimate



## **Coverage History**



	Date	Rating	Target Price	Closing Price
24	31-Jan-2023	Accumulate	INR 1,050	INR 913
25	28-Apr-2023	Accumulate	INR 963	INR 908
26	11-May-2023	Accumulate	INR 1,050	INR 983
27	2-Jun-2023	Reduce	INR 1,050	INR 1,061
28	7-Aug-2023	Accumulate	INR 1,120	INR 1,031
29	20-Dec-2023	Accumulate	INR 1,230	INR 1,050
30	31-Jan-2024	Buy	INR 1,400	INR 1,164
31	7-May-2024	Accumulate	INR 1,470	INR 1,322
32	7-Aug-2024	Accumulate	INR 1,600	INR 1,504
33	24-Oct-2024	Accumulate	INR 1,415	INR 1,255
34	9-Dec-2024	Accumulate	INR 1,330	INR 1,128
35	24-Jan-2025	Accumulate	INR 1,260	INR 1,130

## Guide to Research Rating

BUY	Absolute Return >+20%
ACCUMULATE	Absolute Return +5% to +20%
REDUCE	Absolute Return -5% to +5%
SELL	Absolute Return < -5%



## Disclosures & Confidentiality for non U.S. Investors

The Note is based on our estimates and is being provided to you (herein referred to as the "Recipient") only for information purposes. The sole purpose of this Note is to provide preliminary information on the business activities of the company and the projected financial statements in order to assist the recipient in understanding/ evaluating the Proposal. Nothing in this document should be construed as an advice to buy or sell the securities of companies referred to in this document fine the recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved) and should consult its own advisors to determine the merits and risks of such an investment. Nevertheless, Elara Securities (India) Private Limited or any of its affiliates have not independently verified all the information to its client and would be happy to provide any information in response to specific client queries. Elara Securities (India) Private Limited or any of its affiliates, their directors and the employees may from time to time, effect on the effect of an own account transaction in or deal as principal or agent in or for the securities (India) Private Limited or any of its affiliates, their directors and the employees may from time to time, effect or have effected an own account transaction in or deal as principal or agent in or for the securities (India) Private Limited or any of its affiliates, their directors and the employees may from time to time, effect or have effected an own account transaction in or deal as principal or agent in or for the securities (India) Private Limited or any of its affiliates, private Limited or any of its affiliates, private Limited or any of its affiliates to any registration or be person or published, copied, in whole or in part, for any purpose. This Note is not directed or intended for distribution to, or use by, any person or entities

Any clarifications / queries on the proposal as well as any future communication regarding the proposal should be addressed to Elara Securities (India) Private Limited. It is important to note that any dispute with respect to this research report, would not have access to stock exchange investor redressal forum or arbitration mechanism.

Elara Securities (India) Private Limited was incorporated in July 2007 as a subsidiary of Elara Capital (India) Private Limited.

Elara Securities (India) Private Limited is a SEBI registered Stock Broker in the Capital Market and Futures & Options Segments of National Stock Exchange of India Limited [NSE], in the Capital Market Segment of BSE Limited [BSE] and a Depository Participant registered with Central Depository Services (India) Limited [CDSL].

Elara Securities (India) Private Limited's business, amongst other things, is to undertake all associated activities relating to its broking business.

The activities of Elara Securities (India) Private Limited were neither suspended nor has it defaulted with any stock exchange authority with whom it is registered in last five years. However, during the routine course of inspection and based on observations, the exchanges have issued advise letters or levied minor penalties on Elara Securities (India) Private Limited for minor operational deviations in certain cases. Elara Securities (India) Private Limited has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has the certificate of registration been cancelled by SEBI at any point of time.

Elara Securities (India) Private Limited offers research services primarily to institutional investors and their employees, directors, fund managers, advisors who are registered or proposed to be registered.

Details of Associates of Elara Securities (India) Private Limited are available on group company website www.elaracapital.com

Elara Securities (India) Private Limited is maintaining arms-length relationship with its associate entities.

Research Analyst or his/her relative(s) may have financial interest in the subject company. Elara Securities (India) Private Limited does not have any financial interest in the subject company, whereas its associate entities may have financial interest. Research Analyst or his/her relative does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Elara Securities (India) Private Limited does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Associate entities of Elara Securities (India) Private Limited may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Research Analyst or his/her relative or Elara Securities (India) Private Limited or its associate entities does not have any other material conflict of interest at the time of publication of the Research Report.

Research Analyst or his/her relative(s) has not served as an officer, director or employee of the subject company.

Research analyst or Elara Securities (India) Private Limited have not received any compensation from the subject company in the past twelve months. Associate entities of Elara Securities (India) Private Limited may have received compensation from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities have not managed or co-managed public offering of securities for the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associates have not received any compensation for merchant banking or brokerage services from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company or third party in connection with the Research Report in the past twelve months.

### **Disclaimer & Standard warning**

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

#### Disclaimer for non U.S. Investors

The information contained in this note is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act on such information without appropriate professional advice after a thorough examination of the particular situation.

## **Disclosures for U.S. Investors**

The research analyst did not receive compensation from Godrej Consumer Products Limited.

Elara Capital Inc.'s affiliate did not manage an offering for Godrej Consumer Products Limited.

 $Elara\ Capital\ Inc.'s\ affiliate\ did\ not\ receive\ compensation\ from\ Godrej\ Consumer\ Products\ Limited\ in\ the\ last\ 12\ months.$ 

Elara Capital Inc.'s affiliate does not expect to receive compensation from Godrej Consumer Products Limited in the next 3 months.

### Disclaimer for U.S. Investors

This material is based upon information that we consider to be reliable, but Elara Capital Inc. does not warrant its completeness, accuracy or adequacy and it should not be relied upon as such.

This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities, financial instruments or strategies mentioned herein may not be suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only correct as of the stated date of their issue. Prices, values or income from any securities or investments mentioned in this report may fall against the interests of the investor may get back less than the amount invested. Where an investment is described as being likely to yield income, please note that the amount of income that the investor will receive from such an investment may fluctuate. Where an investment or security is denominated in a different currency to the investor's currency of reference, changes in rates of exchange may have an adverse effect on the value, price or income of or from that investment to the investor. The information contained in this report does not constitute advice on the tax consequences of making any particular investment decision. This material does not take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation of particular securities, financial instruments or strategies to you. Before acting on any recommendation in this material, you should consider whether it is suitable for your particular circumstances and, if necessary, seek professional advice.

Certain statements in this report, including any financial projections, may constitute "forward-looking statements." These "forward-looking statements" are not guarantees of future performance and are based on numerous current assumptions that are subject to significant uncertainties and contingencies. Actual future performance could differ materially from these "forward-looking statements" and financial information.



## India

Elara Securities (India) Private Limited One International Center, Tower 3, 21st Floor, Senapati Bapat Marg, Elphinstone Road (West) Mumbai – 400 013, India Tel: +91 22 6164 8500 Europe Elara Capital Plc.

6th Floor, The Grove, 248A Marylebone Road, London, NW1 6JZ, United Kingdom Tel: +44 20 7486 9733 USA

Elara Securities Inc. 230 Park Avenue, Suite 2415, New York, NY 10169, USA Tel: +1 212 430 5870 Fax: +1 212 208 2501 Asia / Pacific Elara Capital (Asia) Pte.Ltd.

One Marina Boulevard, Level 20, Singapore 018989 Tel: +65 6978 4047



Managing Director

Harendra Kumar | harendra.kumar@elaracapital.com | +91 22 6164 8571



Head of Research

Dr Bino Pathiparampil | bino.pathiparampil@elaracapital.com | +91 22 6164 8572

#### Sales Team



India

Hitesh Danak - hitesh.danak@elaracapital.com - +91 22 6164 8543 Ashok Agarwal - ashok.agarwal@elaracapital.com - +91 22 6164 8558



India, APAC & Australia Sudhanshu Rajpal - sudhanshu.rajpal@elaracapital.com - +91 22 6164 8508 Joshua Saldanha - joshua.saldanha@elaracapital.com - +91 22 6164 8541 Shraddha Shrikhande - shraddha.shrikhande@elaracapital.com - +91 22 6164 8567



India & UK

Prashin Lalvani - prashin.lalvani@elaracapital.com - +91 22 6164 8544



India & US

Karan Rathod - karan.rathod@elaracapital.com - +91 22 6164 8570



Corporate Access, Conference & Events

Anita Nazareth - anita.nazareth@elaracapital.com - +91 22 6164 8520 Tina D'souza - tina.dsouza@elaracapital.com - +91 22 6164 8595

Access our reports on Bloomberg: Type RESP ESEC <GO>

Also available on Thomson & Reuters

### Elara Securities (India) Private Limited

Registered Office Address: One International Center, Tower 3, 21st Floor, Senapati Bapat Marg, Elphinstone Road (West) Mumbai – 400 013, India Tel: +91 22 6164 8500 CIN: U74992MH2007PTC172297 | SEBI Research Analyst Registration No.: INH000000933

Member of BSE Limited and National Stock Exchange of India Limited | SEBI REGN. NO.: INZ 000 238236

Member of Central Depository Services (India) Limited | SEBI REGN. NO.: IN-DP-370-2018

Investor Grievance Email ID: <a href="investor.grievances@elaracapital.com">investor.grievances@elaracapital.com</a> - Tel. +91 22 6164 8509

Compliance Officer: Mr. Anand Rao - Email ID: <a href="anand.rao@elaracapital.com">anand.rao@elaracapital.com</a> - Tel. +91 22 6164 8509